MBRX

Moleculin Biotech Inc

MBRX, USA

Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 portfolio, including WP1066, WP1193, and WP1220, which are immune/transcription modulators designed to inhibit phosphorylated signal transducer and activator of transcription for brain tumors and pancreatic and other cancers. In addition, it is developing WP1122 portfolio, such as WP1122, WP1096, and WP1097 designed to exploit the uses of inhibitors of glycolysis comprising 2-deoxy-D-glucose for the treatment of pathogenic viruses and various cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.

https://moleculin.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
MBRX
stock
MBRX

HC Wainwright Cuts Earnings Estimates for Moleculin Biotech Defense World

Read more →
MBRX
stock
MBRX

Moleculin announces exercise of warrants for $6.8M MSN

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$6.6667

Analyst Picks

Strong Buy

0

Buy

2

Hold

1

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

-0.28

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very High

94.35 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-124.79 %

Low ≤ 2%

High ≥ 10%

Investors

* Institutions hold a combined 2.07% of the total shares of Moleculin Biotech Inc

1.

Vanguard Institutional Extnd Mkt Idx Tr

(0.2889%)

since

2025/07/31

2.

Citigroup Inc

(0.2816%)

since

2025/06/30

3.

XTX Topco Ltd

(0.2451%)

since

2025/06/30

4.

Fidelity Extended Market Index

(0.2198%)

since

2025/07/31

5.

Virtu Financial LLC

(0.1957%)

since

2025/06/30

6.

LPL Financial Corp

(0.1852%)

since

2025/06/30

7.

VERUS CAPITAL PARTNERS, LLC

(0.142%)

since

2025/06/30

8.

Vanguard Group Inc

(0.1021%)

since

2025/06/30

9.

Geode Capital Management, LLC

(0.0909%)

since

2025/06/30

10.

Fidelity Series Total Market Index

(0.0674%)

since

2025/07/31

11.

CAMBRIDGE Invest RESEARCH ADVISORS, INC.

(0.0422%)

since

2025/06/30

12.

BlackRock Inc

(0.0409%)

since

2025/06/30

13.

BB&T Corp.

(0.0347%)

since

2025/06/30

14.

Spartan Total Market Index Pool G

(0.028%)

since

2025/07/31

15.

UBS Group AG

(0.0264%)

since

2025/06/30

16.

Tower Research Capital LLC

(0.0129%)

since

2025/06/30

17.

Stone House Investment Management, LLC

(0.0109%)

since

2025/06/30

18.

Newbridge Financial Services Group, Inc.

(0.0095%)

since

2025/06/30

19.

Fidelity Total Market Index

(0.0068%)

since

2025/07/31

20.

NT Ext Equity Mkt Idx Fd - NL

(0.0058%)

since

2025/06/30

21.

Northern Trust Extended Eq Market Idx

(0.0057%)

since

2025/06/30

22.

NT Ext Equity Mkt Idx Fd - L

(0.0057%)

since

2025/06/30

23.

NT Ext Equity Mkt Idx Fd - DC - NL - T2

(0.0045%)

since

2025/06/30

24.

Morgan Stanley - Brokerage Accounts

(0.0031%)

since

2025/06/30

25.

State St US Extended Mkt Indx NL Cl C

(0.0026%)

since

2025/08/31

26.

SBI Securities Co Ltd

(0.0025%)

since

2025/06/30

27.

Vanguard U.S. Eq Idx £ Acc

(0.0021%)

since

2025/07/31

28.

NT Ext Eq Mkt Indx Fd DC Lending Tier 5

(0.0016%)

since

2025/06/30

29.

Spartan Extended Market Index Pool F

(0.0015%)

since

2025/07/31

30.

NT Ext Eq Mkt Indx Fd DC Lend T3

(0.0014%)

since

2024/12/31

31.

Atlantic Union Bankshares Corp

(0.0013%)

since

2025/06/30

32.

Barclays PLC

(0.0011%)

since

2025/03/31

33.

SSgA U.S. Total Market Index Strategy

(0.0011%)

since

2025/03/31

34.

Bogart Wealth, LLC

(0.001%)

since

2025/06/30

35.

State St US Ttl Mkt Indx NL Cl A

(0.0007%)

since

2025/08/31

36.

Bank of America Corp

(0.0005%)

since

2025/06/30

37.

Northern Trust Wilshire 5000

(0.0003%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-0.68

EPS Estimate

-0.2633

EPS Difference

-0.4167

Surprise Percent

-158.2605%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(1.5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(5.8)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(2)
Momentum
No Momentum(2.5)
Net Net
Not Undervalued (Net-Net)(1)
Quality
Low Quality Business(3)
Value
Overpriced(3)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.